When was Acticor Biotech founded?

Acticor Biotech was founded in 2013 and raised its 1st funding round 2 years after it was founded.

Where is Acticor Biotech located?

Acticor Biotech is headquartered in Paris, France.

Who is the current CEO of Acticor Biotech?

Gilles Avenard of Acticor Biotech.

How many employees does Acticor Biotech have?

As of Mar 01, 2026, the latest employee count at Acticor Biotech is 10 - 49.

Is Acticor Biotech a funded company?

Acticor Biotech is a funded company, having raised a total of $31.4M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 26, 2015.

When was the latest funding round of Acticor Biotech?

Acticor Biotech's latest funding was a $***** Series B round on Nov 06, 2019, with participation from 4 investors. Its primary sector is Neurology. In France, the Neurology sector has seen $95.7M in funding in 2026 to date.

Where does Acticor Biotech rank among its competitors?

Acticor Biotech ranks 67th amongst 232 active competitors, of which 75 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Jasper Therapeutics, which secured $132M in Jul, 2026.

Who are the top competitors of Acticor Biotech?

Acticor Biotech's top competitors include argenx, Alexion and Zai Lab. Among them, Jasper Therapeutics secured the most recent funding round in July, 2026.

Acticor Biotech - 2026 Company Profile, Team, Funding & Competitors

Acticor Biotech is a public company based in Paris (France), founded in 2013. It operates as a Developing immunotherapeutics for treating ischemic stroke. Acticor Biotech has raised $31.4M in funding from investors like GO CAPITAL, Primer Capital and Newton Biocapital. The company has 232 active competitors, including 75 funded and 64 that have exited. Its top competitors include companies like argenx, Alexion and Zai Lab.

Company Details

Developing immunotherapeutics for treating ischemic stroke. The company engages in developing therapeutic monoclonal antibodies for the treatment of ischemic strokes. It offersin developing ACT-017, a humanized antibody for the treatment of cerebral stroke and the platelet glycoprotein VI.

Website: www.acticor-biotech.com
Social

Key Metrics

Founded Year

2013

Location

Paris, France

Stage

Public

Total Funding

$31.4M in 7 rounds

Latest Funding Round

Series B, Nov 06, 2019, $*****

Investors

GO CAPITAL & 8 more

Ranked

67^th among 232 active competitors

Employee Count

10 - 49 as on Mar 01, 2026

Similar Companies

argenx & 286 more

Exit Details

Public

View Acticor Biotech's full profile

Acticor Biotech got listed on Nov 01, 2021.

Click here to take a look at Acticor Biotech's IPO in detail

Acticor Biotech has raised a total funding of $31.4M over 7 rounds. Its first funding round was on Jan 26, 2015. Its latest funding round was a Series B round on Nov 06, 2019 for $*****. 4 investors participated in its latest round. Acticor Biotech has 9 institutional investors.

Here is the list of recent funding rounds of Acticor Biotech:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 06, 2019	9311788	Series B	8761184	7048711	9354127	6285640
Oct 16, 2018	4632929	Series B	4714218	1022940	9479694	Karista & 1 more
Jan 04, 2018	2466216	Series B	4864935	9308699	Primer Capital	Anaxago & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Acticor Biotech's funding rounds and investors

Acticor Biotech's employee count trend

Acticor Biotech has 10 - 49 employees as of Mar 26. Here is Acticor Biotech's employee count trend over the years:

Employee count trend for Acticor Biotech

Uncover Acticor Biotech's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Acticor Biotech include argenx, Alexion and Zai Lab. Here is the list of Top 10 competitors of Acticor Biotech, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
2nd	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
3rd	Zai Lab 2013, Shanghai (China), Public	Developer of drugs for anti-cancer and anti-inflammatory diseases	$160M	HongShan, Rock Springs Capital & 9 others	67/100
4th	Halozyme 1999, San Diego (United States), Public	Developer of drug delivery technologies for the treatment of various diseases	-	Colt Ventures, BB Biotech & 8 others	67/100
5th	XOMA Corporation 1981, Berkeley (United States), Acquired	Developer of antibody-based therapeutics for treating endocrine/metabolic diseases	-	Ignite 500, Hercules Capital & 5 others	65/100
6th	Kodiak Sciences 2009, Palo Alto (United States), Public	Developer of therapeutics to treat retinal diseases	$35.8M	ArrowMark Partners, Perceptive Advisors & 1 others	63/100
7th	Jasper Therapeutics 1999, Redwood City (United States), Series A	Developer of therapeutics for chronic diseases by targeting mast cells and stem cells	$50M	Abingworth, Qiming & 7 others	63/100
8th	IgGenix 2019, San Francisco (United States), Series B	Developer of therapeutic solutions for treating food allergy	$75M	Khosla Ventures, Alexandria & 7 others	63/100
9th	ABL Bio 2016, Seongnam-si (South Korea), Public	Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases	$65M	QUAD, Hana Financial Group & 7 others	63/100
10th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	62/100
67th	Acticor Biotech 2013, Paris (France), Public	Developing immunotherapeutics for treating ischemic stroke	$31.4M	Sylvain Zimmer, Newton Biocapital & 7 others	45/100